Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy received a second CRL as a frontline therapy for unresectable hepatocellular carcinoma (HCC).

Top 5 liver cancer content of 2024 image graphic with health icons

Top 5 Most-Viewed Liver Cancer Content for 2024

By Laura Joszt, MA

December 27th 2024

Advances in therapy are improving outcomes for patients, but the incidence and mortality rates for hepatocellular carcinoma are increasing in the US.

Doctor with human liver anatomy model | Image credit: Jo Panuwat D - stock.adobe.com

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

By Megan Hollasch

December 1st 2024

Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment landscape for HCC.

Man holding liver illustration - SewcreamStudio - stock.adobe.com

Patients With HCC May Avoid Additional Treatment After Complete Response

By Laura Joszt, MA

November 26th 2024

Patients with locally advanced hepatocellular carcinoma (HCC) who achieve a complete response after locoregional therapy and immunotherapy may be able to follow a watch-and-wait protocol.

<1 2

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions